{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T19:43:44Z","timestamp":1786218224117,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,6]],"date-time":"2027-08-06T00:00:00Z","timestamp":1817510400000},"content-version":"am","delay-in-days":339,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["K12-HD103083"],"award-info":[{"award-number":["K12-HD103083"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Perinatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clp.2026.05.001","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:38:20Z","timestamp":1781091500000},"page":"583-599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drugs to Prevent and Treat Venous Thromboembolic Disease During Pregnancy"],"prefix":"10.1016","volume":"53","author":[{"given":"Andra H.","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome J.","family":"Federspiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clp.2026.05.001_bib62","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/1753495X16659401","article-title":"Increased unfractionated heparin requirements with decreasing body mass index in pregnancy","volume":"9","author":"Patil","year":"2016","journal-title":"Obstet Med"},{"issue":"6","key":"10.1016\/j.clp.2026.05.001_bib11","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/j.1875-9114.2011.01049.x","article-title":"Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin","volume":"32","author":"Vandiver","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.clp.2026.05.001_bib1","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.ajog.2005.11.008","article-title":"Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality","volume":"194","author":"James","year":"2006","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.clp.2026.05.001_bib2","first-page":"120","article-title":"Risk factors for venous and arterial thrombosis","volume":"9","author":"Previtali","year":"2011","journal-title":"Blood Transfus"},{"issue":"1","key":"10.1016\/j.clp.2026.05.001_bib3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1161\/01.CIR.19.1.75","article-title":"The discovery of heparin","volume":"19","author":"Mc","year":"1959","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.clp.2026.05.001_bib4","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1161\/01.CIR.69.6.1198","article-title":"Heparin: the contributions of William Henry Howell","volume":"69","author":"Fye","year":"1984","journal-title":"Circulation"},{"issue":"207","key":"10.1016\/j.clp.2026.05.001_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-642-23056-1_1","article-title":"History of heparin","author":"Barrowcliffe","year":"2012","journal-title":"Handb Exp Pharmacol"},{"issue":"6","key":"10.1016\/j.clp.2026.05.001_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22061025","article-title":"From farm to pharma: an overview of industrial heparin manufacturing methods","volume":"22","author":"van der Meer","year":"2017","journal-title":"Molecules"},{"issue":"7138","key":"10.1016\/j.clp.2026.05.001_bib7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(60)92299-6","article-title":"Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial","volume":"1","author":"Barritt","year":"1960","journal-title":"Lancet"},{"issue":"7768","key":"10.1016\/j.clp.2026.05.001_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0140-6736(72)91595-4","article-title":"Efficacy of low doses of heparin in prevention of deep-vein thrombosis after major surgery. A double-blind, randomised trial","volume":"2","author":"Kakkar","year":"1972","journal-title":"Lancet"},{"issue":"6313","key":"10.1016\/j.clp.2026.05.001_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/bmj.284.6313.375","article-title":"Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis","volume":"284","author":"Kakkar","year":"1982","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"2","key":"10.1016\/j.clp.2026.05.001_bib10","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/jth.12085","article-title":"Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature","volume":"11","author":"Romualdi","year":"2013","journal-title":"J Thromb Haemostasis"},{"issue":"22","key":"10.1016\/j.clp.2026.05.001_bib12","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1182\/bloodadvances.2018024802","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy","volume":"2","author":"Bates","year":"2018","journal-title":"Blood Adv"},{"issue":"10365","key":"10.1016\/j.clp.2026.05.001_bib13","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S0140-6736(22)02128-6","article-title":"Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (highlow study): an open-label, multicentre, randomised, controlled trial","volume":"400","author":"Bistervels","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clp.2026.05.001_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/nrcardio.2017.172","article-title":"Milestone 2: warfarin: from rat poison to clinical use","author":"Lim","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"10.1016\/j.clp.2026.05.001_bib15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2125.2006.02806.x","article-title":"Warfarin: almost 60 years old and still causing problems","volume":"62","author":"Pirmohamed","year":"2006","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.clp.2026.05.001_bib16","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1160\/TH06-02-0108","article-title":"Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study","volume":"95","author":"Schaefer","year":"2006","journal-title":"Thromb Haemost"},{"issue":"6076","key":"10.1016\/j.clp.2026.05.001_bib17","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1136\/bmj.1.6076.1564","article-title":"May mothers given warfarin breast-feed their infants?","volume":"1","author":"Orme","year":"1977","journal-title":"Br Med J"},{"issue":"6 Pt 1","key":"10.1016\/j.clp.2026.05.001_bib18","first-page":"938","article-title":"Coumarin derivatives and breast-feeding","volume":"95","author":"Clark","year":"2000","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.clp.2026.05.001_bib19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.thromres.2011.10.037","article-title":"Fondaparinux - data on efficacy and safety in special situations","volume":"129","author":"Nagler","year":"2012","journal-title":"Thromb Res"},{"issue":"21","key":"10.1016\/j.clp.2026.05.001_bib20","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2016-11-709873","article-title":"Heparin-induced thrombocytopenia. Review","volume":"129","author":"Arepally","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clp.2026.05.001_bib21","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/j.1538-7836.2010.03926.x","article-title":"Fondaparinux as an alternative anticoagulant therapy during pregnancy","volume":"8","author":"Knol","year":"2010","journal-title":"J Thromb Haemostasis"},{"issue":"2","key":"10.1016\/j.clp.2026.05.001_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/GRF.0000000000000357","article-title":"Prevention and management of thromboembolism in pregnancy when heparins are not an option","volume":"61","author":"James","year":"2018","journal-title":"Clin Obstet Gynecol"},{"issue":"3\u20134","key":"10.1016\/j.clp.2026.05.001_bib23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ejps.2010.08.001","article-title":"Development and in vivo bioavailability study of an oral fondaparinux delivery system","volume":"41","author":"Vetter","year":"2010","journal-title":"Eur J Pharmaceut Sci"},{"issue":"13","key":"10.1016\/j.clp.2026.05.001_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"15","key":"10.1016\/j.clp.2026.05.001_bib25","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1182\/bloodadvances.2019000572","article-title":"Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world","volume":"3","author":"Aryal","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clp.2026.05.001_bib26","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2147\/TCRM.S68010","article-title":"Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review","volume":"11","author":"Mandernach","year":"2015","journal-title":"Therapeut Clin Risk Manag"},{"issue":"2","key":"10.1016\/j.clp.2026.05.001_bib27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3949\/ccjm.88a.19133","article-title":"Reversal of direct oral anticoagulants: highlights from the anticoagulation forum guideline","volume":"88","author":"Gorr","year":"2021","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.clp.2026.05.001_bib28","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"Lopez-Lopez","year":"2017","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.clp.2026.05.001_bib29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11239-015-1309-0","article-title":"Guidance for the treatment and prevention of obstetric-associated venous thromboembolism","volume":"41","author":"Bates","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.clp.2026.05.001_bib30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.thromres.2018.07.022","article-title":"Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review","volume":"169","author":"Lameijer","year":"2018","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.clp.2026.05.001_bib31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.amjmed.2021.10.023","article-title":"First trimester anticoagulant exposure and adverse pregnancy outcomes in women with preconception venous thromboembolism: a nationwide cohort study","volume":"135","author":"Sogaard","year":"2022","journal-title":"Am J Med"},{"issue":"suppl 1","key":"10.1016\/j.clp.2026.05.001_bib32","first-page":"32","article-title":"Outcome of DOAC exposure during pregnancy","volume":"4","author":"Beyer-Westendorf","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"10.1016\/j.clp.2026.05.001_bib33","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41569-025-01144-z","article-title":"Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism","volume":"22","author":"Capodanno","year":"2025","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"10.1016\/j.clp.2026.05.001_bib34","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clp.2026.05.001_bib35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemostasis"},{"issue":"3","key":"10.1016\/j.clp.2026.05.001_bib37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0267659115583525","article-title":"Bivalirudin as an adjunctive anticoagulant to heparin in the treatment of heparin resistance during cardiopulmonary bypass-assisted cardiac surgery","volume":"31","author":"McNair","year":"2016","journal-title":"Perfusion"},{"issue":"1","key":"10.1016\/j.clp.2026.05.001_bib38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MBC.0000000000000879","article-title":"Bivalirudin anticoagulation to overcome heparin resistance in a neonate with cerebral sinovenus thrombosis","volume":"31","author":"Bertamino","year":"2020","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"20","key":"10.1016\/j.clp.2026.05.001_bib39","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1182\/bloodadvances.2020002963","article-title":"Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses","volume":"4","author":"Morgan","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clp.2026.05.001_bib40","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40256-020-00450-w","article-title":"A review of bivalirudin for pediatric and adult mechanical circulatory support","volume":"21","author":"Taylor","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"10.1016\/j.clp.2026.05.001_bib41","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00132580-200103000-00010","article-title":"Bivalirudin: a new approach to anticoagulation. Review","volume":"3","author":"Nawarskas","year":"2001","journal-title":"Heart Dis"},{"issue":"7","key":"10.1016\/j.clp.2026.05.001_bib42","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/CIRCRESAHA.112.264903","article-title":"Translational success stories: development of direct thrombin inhibitors. Research Support, Non-U.S. Gov\u2019t Review","volume":"111","author":"Coppens","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.clp.2026.05.001_bib43","unstructured":"Highlights of prescribing information for ANGIOMAX\u00ae (bivalirudin) 1\u201320 (2016)."},{"issue":"8","key":"10.1016\/j.clp.2026.05.001_bib44","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2165\/00003088-200443080-00001","article-title":"Drug transfer and metabolism by the human placenta. Research support, non-U.S. Gov\u2019t review","volume":"43","author":"Syme","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.clp.2026.05.001_bib63","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1053\/j.jvca.2025.05.005","article-title":"Pregnancy anticoagulation management in a patient with a mechanical heart valve and heparin-induced thrombocytopenia","volume":"39","author":"Federspiel","year":"2025","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"1","key":"10.1016\/j.clp.2026.05.001_bib45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-0034-1398382","article-title":"Efficacy of argatroban in critically ill patients with heparin resistance: a retrospective analysis","volume":"41","author":"Treichl","year":"2015","journal-title":"Semin Thromb Hemost"},{"issue":"10293","key":"10.1016\/j.clp.2026.05.001_bib46","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S0140-6736(21)01238-1","article-title":"SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban","volume":"397","author":"Guetl","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clp.2026.05.001_bib47","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jocn.2021.06.002","article-title":"Effects of argatroban therapy for stroke patients: a meta-analysis","volume":"90","author":"Hou","year":"2021","journal-title":"J Clin Neurosci"},{"issue":"4","key":"10.1016\/j.clp.2026.05.001_bib48","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0885066621993739","article-title":"Argatroban anticoagulation for adult extracorporeal membrane oxygenation: a systematic review","volume":"37","author":"Geli","year":"2022","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.clp.2026.05.001_bib49","unstructured":"Argatroban injection label (FDA) 4\u201323."},{"issue":"4","key":"10.1016\/j.clp.2026.05.001_bib50","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1447-0756.2011.01758.x","article-title":"Argatroban therapy for heparin-induced thrombocytopenia during pregnancy in a woman with hereditary antithrombin deficiency","volume":"38","author":"Tanimura","year":"2012","journal-title":"J Obstet Gynaecol Res"},{"issue":"12","key":"10.1016\/j.clp.2026.05.001_bib51","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1592\/phco.28.12.1531","article-title":"Successful use of argatroban during the third trimester of pregnancy: case report and review of the literature","volume":"28","author":"Young","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.clp.2026.05.001_bib52","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1213\/ANE.0b013e3181e9ed15","article-title":"The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations","volume":"111","author":"Bolliger","year":"2010","journal-title":"Anesth Analg"},{"issue":"8","key":"10.1016\/j.clp.2026.05.001_bib53","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/17425255.2016.1194395","article-title":"The toxicology of heparin reversal with protamine: past, present and future","volume":"12","author":"Sokolowska","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"10.1016\/j.clp.2026.05.001_bib54","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/MBC.0b013e3283494b3c","article-title":"Protamine reversal of low molecular weight heparin: clinically effective?","volume":"22","author":"van Veen","year":"2011","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2 Suppl","key":"10.1016\/j.clp.2026.05.001_bib55","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.clp.2026.05.001_bib56","doi-asserted-by":"crossref","first-page":"314","DOI":"10.7861\/clinmedicine.18-4-314","article-title":"The reversal of anticoagulation in clinical practice","volume":"18","author":"Thomas","year":"2018","journal-title":"Clin Med"},{"issue":"5","key":"10.1016\/j.clp.2026.05.001_bib57","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.thromres.2008.07.007","article-title":"Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC","volume":"123","author":"Desmurs-Clavel","year":"2009","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.clp.2026.05.001_bib58","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for Dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.clp.2026.05.001_bib59","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clp.2026.05.001_bib60","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.25475","article-title":"Reversal of direct oral anticoagulants: guidance from the anticoagulation forum","volume":"94","author":"Cuker","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clp.2026.05.001_bib61","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1051\/ject\/200537296","article-title":"Use of bivalirudin as an anticoagulant during cardiopulmonary bypass","volume":"37","author":"Veale","year":"2005","journal-title":"J Extra Corpor Technol"}],"container-title":["Clinics in Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510826000497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510826000497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T19:24:12Z","timestamp":1786217052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0095510826000497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0095510826000497"],"URL":"https:\/\/doi.org\/10.1016\/j.clp.2026.05.001","relation":{},"ISSN":["0095-5108"],"issn-type":[{"value":"0095-5108","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs to Prevent and Treat Venous Thromboembolic Disease During Pregnancy","name":"articletitle","label":"Article Title"},{"value":"Clinics in Perinatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clp.2026.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}